Piper Jaffray Cuts Price Target on Antares Pharma (ATRS) Following 2Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St climbs as Mideast tensions ease, Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- The next banking crisis may come from cyberattacks, not credit losses: JPMorgan
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Micron ships 245TB data center SSD, claims world's highest capacity
- Triller to acquire SpaceX exposure as treasury asset via fund structure
- TD Cowen: 'Sober View Suggests Structural Alcohol Risks Are Overblown'
Antares Pharma's (ATRS) CFO Resigns
August 11, 2016 7:15 AM EDTAntares Pharma (NASDAQ: ATRS) disclosed in an SEC filing:
On August 5, 2016, Antares Pharma, Inc. (the Company) received a written notice of resignation from James E. Fickenscher, the Companys Senior Vice President and Chief Financial Officer. Mr. Fickenschers resignation will become effective September 4, 2016.... More
Antares Pharma (ATRS) Reports In-Line Q2 EPS
August 9, 2016 7:50 AM EDTAntares Pharma (NASDAQ: ATRS) reported Q2 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $11 million.
For earnings history and earnings-related data on Antares Pharma (ATRS) click here.
... More